Literature DB >> 27462018

Effects of different ligands on epidermal growth factor receptor (EGFR) nuclear translocation.

Jerusa A Q A Faria1, Carolina de Andrade1, Alfredo M Goes1, Michele A Rodrigues2, Dawidson A Gomes3.   

Abstract

The epidermal growth factor receptor (EGFR) is activated through binding to specific ligands and generates signals for proliferation, differentiation, migration, and cell survival. Recent data show the role of nuclear EGFR in tumors. Although many EGFR ligands are upregulated in cancers, little is known about their effects on EGFR nuclear translocation. We have compared the effects of six EGFR ligands (EGF, HB-EGF, TGF-α, β-Cellulin, amphiregulin, and epiregulin) on nuclear translocation of EGFR, receptor phosphorylation, migration, and proliferation. Cell fractionation and confocal immunofluorescence detected EGFR in the nucleus after EGF, HB-EGF, TGF-α and β-Cellulin stimulation in a dose-dependent manner. In contrast, amphiregulin and epiregulin did not generate nuclear translocation of EGFR. EGF, HB-EGF, TGF-α and β-Cellulin showed correlations between a higher rate of wound closure and increased phosphorylation of residues in the carboxy-terminus of EGFR, compared to amphiregulin and epiregulin. The data indicate that EGFR is translocated to the nucleus after stimulation with EGF, HB-EGF, TGF-α and β-Cellulin, and that these ligands are related to increased phosphorylation of EGFR tyrosine residues, inducing migration of SkHep-1 cells.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell migration; EGFR ligands; Epidermal growth factor receptor; Nuclear translocation; Proliferation; Tyrosine phosphorylation sites

Mesh:

Substances:

Year:  2016        PMID: 27462018      PMCID: PMC4977159          DOI: 10.1016/j.bbrc.2016.07.097

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  34 in total

1.  Insulin induces calcium signals in the nucleus of rat hepatocytes.

Authors:  Michele A Rodrigues; Dawidson A Gomes; Viviane A Andrade; M Fatima Leite; Michael H Nathanson
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

2.  Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer.

Authors:  Hui-Wen Lo; Weiya Xia; Yongkun Wei; Mohamed Ali-Seyed; Shiu-Feng Huang; Mien-Chie Hung
Journal:  Cancer Res       Date:  2005-01-01       Impact factor: 12.701

3.  Nuclear localization of EGF receptor and its potential new role as a transcription factor.

Authors:  S Y Lin; K Makino; W Xia; A Matin; Y Wen; K Y Kwong; L Bourguignon; M C Hung
Journal:  Nat Cell Biol       Date:  2001-09       Impact factor: 28.824

Review 4.  Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands.

Authors:  Shigeki Higashiyama; Hidehiko Iwabuki; Chie Morimoto; Miki Hieda; Hirofumi Inoue; Natsuki Matsushita
Journal:  Cancer Sci       Date:  2008-02       Impact factor: 6.716

5.  Different epidermal growth factor (EGF) receptor ligands show distinct kinetics and biased or partial agonism for homodimer and heterodimer formation.

Authors:  Jennifer L Macdonald-Obermann; Linda J Pike
Journal:  J Biol Chem       Date:  2014-08-01       Impact factor: 5.157

6.  Epiregulin is more potent than EGF or TGFalpha in promoting in vitro wound closure due to enhanced ERK/MAPK activation.

Authors:  Bradley K Draper; Toshi Komurasaki; Mari K Davidson; Lillian B Nanney
Journal:  J Cell Biochem       Date:  2003-08-15       Impact factor: 4.429

Review 7.  Functional selectivity of EGF family peptide growth factors: implications for cancer.

Authors:  Kristy J Wilson; Jennifer L Gilmore; John Foley; Mark A Lemmon; David J Riese
Journal:  Pharmacol Ther       Date:  2008-12-16       Impact factor: 12.310

8.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Authors:  Shirin Khambata-Ford; Christopher R Garrett; Neal J Meropol; Mark Basik; Christopher T Harbison; Shujian Wu; Tai W Wong; Xin Huang; Chris H Takimoto; Andrew K Godwin; Benjamin R Tan; Smitha S Krishnamurthi; Howard A Burris; Elizabeth A Poplin; Manuel Hidalgo; Jose Baselga; Edwin A Clark; David J Mauro
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

Review 9.  Nuclear EGFR as a molecular target in cancer.

Authors:  Toni M Brand; Mari Iida; Neha Luthar; Megan M Starr; Evan J Huppert; Deric L Wheeler
Journal:  Radiother Oncol       Date:  2013-07-03       Impact factor: 6.280

10.  Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.

Authors:  Yukio Nishimura; Kiyoko Yoshioka; Biborka Bereczky; Kazuyuki Itoh
Journal:  Mol Cancer       Date:  2008-05-21       Impact factor: 27.401

View more
  14 in total

1.  Translocation of Epidermal Growth Factor (EGF) to the nucleus has distinct kinetics between adipose tissue-derived mesenchymal stem cells and a mesenchymal cancer cell lineage.

Authors:  Camila Cristina Fraga Faraco; Jerusa Araújo Quintão Arantes Faria; Marianna Kunrath-Lima; Marcelo Coutinho de Miranda; Mariane Izabella Abreu de Melo; Andrea da Fonseca Ferreira; Michele Angela Rodrigues; Dawidson Assis Gomes
Journal:  J Struct Biol       Date:  2017-12-19       Impact factor: 2.867

2.  Inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) is overexpressed in cholangiocarcinoma and its expression correlates with S100 calcium-binding protein A4 (S100A4).

Authors:  Michele A Rodrigues; Dawidson A Gomes; Ana Luiza Cosme; Marcelo Dias Sanches; Vivian Resende; Geovanni D Cassali
Journal:  Biomed Pharmacother       Date:  2021-11-16       Impact factor: 6.529

3.  Prognostic implications of epidermal growth factor receptor variant III expression and nuclear translocation in Chinese human gliomas.

Authors:  Kaiyuan Yang; Xiaohui Ren; Liyuan Tao; Peipei Wang; Haihui Jiang; Li Shen; Yiming Zhao; Yong Cui; Mingxiao Li; Song Lin
Journal:  Chin J Cancer Res       Date:  2019-02       Impact factor: 5.087

Review 4.  Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma.

Authors:  Yongchang Lai; Zhijian Zhao; Tao Zeng; Xiongfa Liang; Dong Chen; Xiaolu Duan; Guohua Zeng; Wenqi Wu
Journal:  Cancer Cell Int       Date:  2018-03-05       Impact factor: 5.722

Review 5.  The NAE Pathway: Autobahn to the Nucleus for Cell Surface Receptors.

Authors:  Poonam Shah; Alexandre Chaumet; Stephen J Royle; Frederic A Bard
Journal:  Cells       Date:  2019-08-16       Impact factor: 6.600

Review 6.  Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response.

Authors:  Mahmoud Toulany
Journal:  Genes (Basel)       Date:  2019-01-04       Impact factor: 4.096

7.  Selective Suppression of Cell Growth and Programmed Cell Death-Ligand 1 Expression in HT1080 Fibrosarcoma Cells by Low Molecular Weight Fucoidan Extract.

Authors:  Kiichiro Teruya; Yoshihiro Kusumoto; Hiroshi Eto; Noboru Nakamichi; Sanetaka Shirahata
Journal:  Mar Drugs       Date:  2019-07-19       Impact factor: 5.118

Review 8.  The nuclear transportation routes of membrane-bound transcription factors.

Authors:  Yang Liu; Peiyao Li; Li Fan; Minghua Wu
Journal:  Cell Commun Signal       Date:  2018-04-03       Impact factor: 5.712

9.  ErbB3 Ligand Heregulin1 Is a Major Mitogenic Factor for Uncontrolled Lung Cancer Cell Proliferation.

Authors:  Shiqi Ma; Shijun Jia; Yuan Ren; Bangrong Cao; Xiao Zha; Jintao He; Changmin Chen
Journal:  Neoplasia       Date:  2019-03-02       Impact factor: 5.715

10.  Blood and Salivary Amphiregulin Levels as Biomarkers for Asthma.

Authors:  Mahmood Yaseen Hachim; Noha Mousaad Elemam; Rakhee K Ramakrishnan; Laila Salameh; Ronald Olivenstein; Ibrahim Yaseen Hachim; Thenmozhi Venkatachalam; Bassam Mahboub; Saba Al Heialy; Rabih Halwani; Qutayba Hamid; Rifat Hamoudi
Journal:  Front Med (Lausanne)       Date:  2020-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.